DNAPrint Genomics Inc., of Sarasota, Fla., said Harvard University received a notice of allowance for 20 claims that cover diagnostic uses CD59, a marker for diabetes licensed by the company in a January agreement. The company also received a notice of allowance for a patent covering methods for identifying links between gene sequences and phenotypes, both physical and medical.
DOV Pharmaceutical Inc., of Hackensack, N.J., received a notice of allowance for a patent covering a polymorphic, or crystalline, form of bicifadine analgesic. The patent is expected to run through at least 2024.
EntreMed Inc., of Rockville, Md., was issued U.S. Patent No. 7,012,070, covering methods of treatment for a broad range of indications with its lead compound, 2-methoxyestradiol (2ME2), which is in Phase II cancer trials.
GenoMed Inc., of St. Louis, received U.S. Patent No. 6,998,404, titled "Treatment or prevention of acute renal failure," which covers its use of an existing intravenous medication.
Geron Corp., of Menlo Park, Calif., was granted U.S. Patent 7,033,831, covering methods for scalable production of pancreatic islet cells from human embryonic stem cells for use in cell-based treatments for diabetes.
Introgen Therapeutics Inc., of Austin, Texas, received U.S. Patent No. 7,033,750, covering methods used to produce adenoviral p53, expanding the company's protection for its lead cancer therapy, Advexin.
Isis Pharmaceuticals Inc., of Carlsbad, Calif., was issued U.S. Patent No. 7,015,315, covering antisense drugs with modified sugars, which include the company's second-generation chemistry, generation 2.2 chemistry and numerous other sugar-modified antisense compounds.
Nanogen Inc., of San Diego, was issued U.S. Patent No. 6,989,086, titled "Channel-less Separation of Bioparticles on a Bioelectronic Chip by Dielectrophoresis," relating to a method of separating biomolecules or cell particles on a chip. Nanogen also was issued U.S. Patent Nos. 7,014,854, covering the use of immune system modulation to remove proteins associated with Alzheimer's disease, and 7,015,004, relating to the isolation and use of a biomarker to diagnose metabolic syndrome.
Oncolytics Biotech Inc., of Calgary, Alberta, received U.S. Patent No. 7,014,847, titled "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders
OxiGene Inc., of Waltham, Mass., received U.S. Patent No. 7,018,987, titled "Synthesis of Combretastatin A4 Prodrugs and Trans-Isomers Thereof," which covers methods of synthesizing its lead drug candidate, CA4P.
Primagen Holding BV, of Amsterdam, The Netherlands, was issued a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment, such as highly active HIV-1 treatment and other antiviral therapies using nucleoside analogues.
Pro-Pharmaceuticals Inc., of Newton, Mass., received U.S. Patent No. 7,012,068, titled "Co-Administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer."
Seattle Genetics Inc., of Bothell, Wash., received a notice of allowance for a patent titled "Recombinant Anti-CD30 Antibodies and Uses Thereof," covering methods of using certain anti-CD30 antibodies to treat Hodgkin's disease, both as a single agent and in combination with other therapies.
Sirna Therapeutics Inc., of San Francisco, was granted U.S. Patent No. 7,022,828, covering any chemically modified siRNA targeting I Kappa B kinase-gamma, and any siRNA sequence used against the gene.
Solexa Inc., of Hayward, Calif., was granted U.S. Patent No. 6,969,488, relating to its portfolio of intellectual property around the use of microbeads for applications, such as sequencing by ligation.
Vivus Inc., of Mountain View, Calif., received U.S. Patent No. 6,978,945, relating to the Metered Dose Transdermal Spray, which Vivus uses in two of its women's sexual health products in development: Testosterone MDTS for decreased libido and Evamist for menopause.